Baird analyst Brian Skorney lowered 3Q16 Hep C estimates and his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE